Developing Site -Specifically Modified ADCs: Using A Chemoenzymatic Approach

Summary:  Antibody-drug conjugates (ADCs) approach is attractive to the oncology therapeutic area and relies upon tethering a cytotoxic drug (generally) to a monoclonal antibody that targets the drug to the tumour cell and, upon internalisation, releases its toxic payload to the cell. The advantage of the approach is that there is a highly-efficient delivery of a lethal level of drug to a tumour. Such concentrations may be impossible to achieve in the patient because of cost and toxicity of systemic administration. This eBook include articles from various Elsevier journals and highlight the most up-to-date developments in ADC technology.

Click here to download eBook.